Business Wire

SymphonyAI Introduces Symphony Risk Intelligence, an Agent-native Platform That Unlocks Always-on Compliance™ — the Catalyst for Transforming the Financial Crime Operating Model

24.9.2026 16:04:00 EEST | Business Wire | Press release

Share

SymphonyAI today introduced Symphony Risk Intelligence (SRI), an enterprise-grade, agent-native platform built to unlock Always-on Compliance™. This is a critical shift from periodic to continuous risk and compliance management, in which institutions continuously reassess risk and adapt controls as regulations, threats and business activity change, rather than waiting for the next scheduled review.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260924914614/en/

Current approaches have reached their structural limits. The FinCrime Frontier 2026–27 Report, released recently by SymphonyAI and AML Intelligence, finds just 4.7% of financial institutions continuously update their compliance monitoring and controls as risk changes, and 76.3% still review alerts manually or with only partial automation — barely changed year over year. Yet standing still isn't an option: the regulatory climate is at a major inflection point across every market, from FinCEN's AML/CFT reforms in the U.S. to the EU AML Package and AMLA, to tightening oversight from AUSTRAC and Singapore's MAS. Business complexity is reaching its own tipping point: criminal typologies shift faster than review cycles can adapt, business models, payment rails and new financial instruments keep outrunning static rule sets, and competing on speed and choice keeps pushing institutions to offer more with less friction, widening the risk surface further.

“Financial crime compliance has reached the limits of static, episodic approaches to managing risk,” said John Edison, President, SymphonyAI Financial Services. “Always-on Compliance™, delivered through our Symphony Risk Intelligence platform, is how we help institutions continuously operationalize financial crime controls, institutional judgment and governed agentic orchestration in response to evolving threats, regulatory changes and new policies. SymphonyAI has spent 25 years working alongside some of the world’s most complex financial institutions, and SRI brings that experience together with a new generation of intelligence and governed AI to help our customers and partners make that shift real.”

At the core of SRI is a System of Intelligence that continuously determines what has changed in regulations, threats, policy and customer risk, where it matters, and what action it requires. That determination directs the work: agents take on detection, triage, investigation and reporting based on what has just changed, not on a fixed schedule or a static set of rules — so compliance keeps pace with risk instead of catching up to it after the fact. Governance runs alongside that continuous direction, not after it: defined boundaries on what each agent can do, human oversight configurable from semi- to fully autonomous, and a complete audit trail behind every decision — extended on the same terms to agents an institution builds itself.

Rather than replacing the systems of record institutions depend on for business continuity, SRI augments and hydrates them — keeping their data current and surfacing risks that static rules would miss. Institutions can start with SRI wherever the need is greatest, whether that's a single targeted problem or a full domain transformation such as end-to-end transaction monitoring — closing coverage gaps in weeks rather than months, absorbing manual work without adding headcount, cutting alert noise while surfacing real risk, standing audit-ready by default rather than scrambling to prepare for one, and cutting the cost of running compliance day-to-day. Working with some of the world's top-tier financial institutions, these capabilities have driven up to 80% fewer false positives, 70% faster case resolution and a six-fold increase in investigator productivity.

“SymphonyAI’s new platform/framework recasts the workflows, data management and analytics in financial crime and risk intelligence from an AI-native perspective,” said Sid Dash, Chief Researcher at Chartis. “Leveraging its experience in developing its portfolio of solutions and its strong investment in core AI technology, SymphonyAI is transforming the ways financial institutions and services providers build solutions (whether enterprise, departmental or specific point solutions) to solve their financial crime, compliance and decisioning challenges.”

This announcement follows significant industry recognition for SymphonyAI. The company was ranked in the top third of Chartis Research's RiskTech100® 2027 for the second year and received a category award for Agentic Platforms - Compliance.

SymphonyAI was also named a Leader in The Forrester Wave™: Financial Crime Management Solutions, Q3 2026, receiving the highest combined Strategy and Offering score among all 15 vendors evaluated — Forrester's evaluation of financial crime management as a unified discipline, bringing together fraud, AML and KYC in a single market assessment.

To learn more about Always-on Compliance and Symphony Risk Intelligence, visit https://www.symphonyai.com/financial-services/platform

About SymphonyAI

SymphonyAI Financial Services provides AI software to tackle the most complex challenges in financial crime detection, risk management, and compliance. With a global presence and more than 25 years of industry expertise, it combines deep domain knowledge with the latest AI innovation. Its pioneering agent-led solutions enable the Always-on Compliance™ operating model, helping financial institutions strengthen risk coverage, reduce costs, and adapt to changing threats and regulations. Its mission is to make the financial system safer while enabling institutions to grow with confidence. Learn more at symphonyai.com/financial-services.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260924914614/en/

Contacts

Media Contact
SymphonyAI
media@symphonyai.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye